DE NOVO MYELODYSPLASTIC SYNDROME
Clinical trials for DE NOVO MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new DE NOVO MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for DE NOVO MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to knock out tough blood cancers
Disease control Recruiting nowThis study is testing a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) to see how well they work against aggressive forms of blood cancer, including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), and chronic my…
Matched conditions: DE NOVO MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug cocktail tested to fight aggressive blood cancers
Disease control Recruiting nowThis study is testing a combination of five drugs to treat adults newly diagnosed with specific, aggressive forms of blood cancer. The goal is to see if this combination is safe and effective at putting the cancer into remission. The treatment involves chemotherapy and a targeted…
Matched conditions: DE NOVO MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Immune-Targeting drug cocktail tested for rare blood disorders
Disease control Recruiting nowThis study is testing a combination of four drugs to see if they can improve blood counts in adults with aplastic anemia or low-risk myelodysplastic syndrome (MDS). The treatment aims to calm an overactive immune system that may be attacking the bone marrow, while also boosting w…
Matched conditions: DE NOVO MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC